English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In this paper, results of the one year follow-up on the effects of ticlopidine on platelet aggregation (PA), other blood parameters and peripheral hemodynamics in patients with arteriosclerosis are reported. We measured PA, plasma /3-thromboglobulin (, 3-TG), plasma euglobulin lysis time (ELT), plasma lipids and peripheral hemodynamics in 9 patients (mean age 64. 4 years) including chronic state of ischemic heart disease, cerebral infarction and arteriosclerosis obliterans before treatment with oral administration of 300 mg of ticlopidine per day, at 1, 3, 6 and 12 months during treatment. Blood flow (BF) and maximum venous outflow of the forearm and calf were measured by venous occlusion plethysmography using strain gauge to investigate peripheral hemodynamics. PA, induced by ADP, collagen, adrenaline and arachidonic acid, decreased significantly at 1 and 12 months following ticlopidine treatment. No significant change in other blood parameters was found following the treatment except the increase of plasma phospholipid at 12 months following the treatment. Significant increase in BF of the bilateral forearm and calf was observed at 12 months following the treatment. These results show that an anti-platelet drug, ticlopidine may have beneficial effects on peripheral hemodynamics in the treatment of patients with arteriosclerosis.

One year follow-up on the effects of ticlopidine on platelet aggregation, other blood parameters and peripheral hemodynamics